Orionis Biosciences
Andrew Littlehale has a strong background in finance, holding various leadership positions in the biotechnology and pharmaceutical industries. Andrew most recently served as the Vice President Finance at Orionis Biosciences since October 2018. Prior to that, they were the Chief Financial Officer at Macrolide Pharmaceuticals from March 2016 to September 2018. Andrew also held the position of EVP Finance at Synlogic, Inc. from February 2015 to March 2016. From July 2010 to January 2015, they served as the Vice President of Finance at FORMA Therapeutics. Earlier in their career, they were the VP of Finance & Administration at Aeris Therapeutics from April 2005 to July 2010 and the Controller at Genomics Collaborative from 2000 to 2004.
Andrew Littlehale attended Wheaton College from 1992 to 1996, where they earned a Bachelor of Arts degree. Andrew then went on to pursue further education at Suffolk University's Sawyer Business School from 2005 to 2007, where they obtained a Master of Business Administration (MBA) degree.
This person is not in any offices
Orionis Biosciences
1 followers
Orionis Biosciences operates in the healthcare industry focusing on the biotechnology business and innovation.The company is an early-stage drug discovery and development biotechnology company fueled by a suite of disruptive technologies to advance innovative medicines for the treatment of diseases with high unmet medical needs – with an initialinternal focus in oncology and immunotherapies.Orionis Biosciences has research facilities in the Boston area (Headquarters in Waltham, MA, USA) and Ghent (Belgium), and is operated by a world class team of entrepreneurs, scientists and transatlantic network of investors, in concert with strategic research and development collaborations. The latter includes collaborations with VIB (Belgium), Orionis Biosciences co-founding institution.